NCT00354445Unknown4 期
A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement
适应症
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 1,000
- 试验地点
- 2
研究概览
简要总结
The purpose of this study is to explore the safety and efficacy of Macugen given as maintenance therapy in patients who have had initial success with another AMD treatment. Patients must have 1, but not more than 3 prior treatments for Neovascular AMD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subfoveal CNV secondary to AMD
- •At least 1 but not more than 3 prior treatments for AMD
排除标准
- •Subfoveal scar or subfoveal atrophy
- •Significant media opacities, including cataract, which might interfere with visual acuity
研究者
研究点 (2)
Loading locations...
相似试验
终止
不适用
Macugen Observational StudyVascular Endothelial Growth FactorMacular DegenerationNCT00735943Pfizer22
已完成
2 期
Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the MaculaDiabetic Macular EdemaNCT00040313Eyetech Pharmaceuticals
已完成
3 期
A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.Chronic Thromboembolic Pulmonary HypertensionPulmonary Arterial HypertensionNCT03422328Actelion151
已完成
3 期
Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid ArthritisRheumatoid ArthritisNCT00691028Tanabe Pharma Corporation327
终止
4 期
Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)Age-Related Macular DegenerationNCT00134667Eyetech Pharmaceuticals360